Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

When I last covered Allogene Therapeutics (NASDAQ: ALLO ), my tentative optimism was tempered by the early stage of development that the company continues to work in. I suggested at the time that there wasI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of investin ...